Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 2Phase 2 1

Status

Completed 4Terminated 1

Sponsor Class

INDUSTRY 5OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Other hematologic neoplasm 5

Conditions

Leukemia, Myeloid, Acute 5Ovarian Neoplasms 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Carcinoma, Hepatocellular 1

Interventions

Azacitidine 142Cytarabine 109venetoclax 94fludarabine 35Daunorubicin 34Decitabine 32Idarubicin 26gilteritinib 24Cyclophosphamide 21quizartinib 15midostaurin 15Mitoxantrone 14Etoposide 14Granulocyte Colony-Stimulating Factor 12Gemtuzumab 11CPX-351 11decitabine and cedazuridine drug combination 10Drug Therapy 10cc-486 9Filgrastim 9Clofarabine 9ivosidenib 8Injections 8Dexamethasone 8pevonedistat 7fludarabine phosphate 7AP 1903 reagent 7posaconazole 6magrolimab 6glasdegib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia, Myeloid, Acute × guadecitabine × Clear all
NCT02920008 2024-08-28

Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia

Astex Pharmaceuticals, Inc.

Phase 3 Completed
302 enrolled 23 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02348489 2024-08-27

SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction

Astex Pharmaceuticals, Inc.

Phase 3 Completed
815 enrolled 19 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03603964 2024-08-27

Guadecitabine Extension Study

Astex Pharmaceuticals, Inc.

Phase 2 Terminated
35 enrolled 10 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02293993 2021-03-05

Phase 1 Study of SGI-110 in Patients With Acute Myeloid Leukemia

Otsuka Pharmaceutical Co., Ltd.

Phase 1 Completed
21 enrolled 13 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02892318 2020-03-13

A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML)

Hoffmann-La Roche

Phase 1 Completed
40 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡